Contact Information:

Media Contact

Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306

Twitter: BIDMCNews

http://www.bidmc.harvard.edu




Kredyty mieszkaniowe Kredyty mieszkaniowe

Sprawdź aktualny ranking najlepszych kredytów mieszkaniowych w Polsce - atrakcyjne kredytowanie nieruchomości.
PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION
RSS - Press News Release
Add Press Release

Researchers identify drug target for ATRA, the first precision cancer therapy

Discovery offers a new way to fight cancer by targeting the Pin1 enzyme


2015-04-13
(Press-News.org) BOSTON - Targeted cancer therapies work by blocking a single oncogenic pathway to halt tumor growth. But because cancerous tumors have the unique ability to activate alternative pathways, they are often able to evade these therapies -- and regrow. Moreover, tumors contain a small portion of cancer stem cells that are believed to be responsible for tumor initiation, metastasis and drug resistance. Thus, eradicating cancer stem cells may be critical for achieving long-lasting remission, but there are no drugs available that specifically attack cancer stem cells.

Now a research team led by investigators in the Cancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC), has identified an inhibitor of the Pin1 enzyme that can address both of these challenges in acute promyelocytic leukemia (APL) and triple negative breast cancer.

Their surprising discovery demonstrates that the vitamin A derivative ATRA (all-trans retinoic acid), a treatment for APL that is considered to be the first example of modern targeted cancer therapy, can block multiple cancer-driving pathways and, at the same time, eliminate cancer stem cells by degrading the Pin1 enzyme. Reported online today in Nature Medicine, these novel findings suggest a promising new way to fight cancer - particularly cancers that are aggressive or drug resistant.

"Pin1 changes protein shape through proline-directed phosphorylation, which is a major control mechanism for disease," explains co-senior author Kun Ping Lu, MD, PhD, Director of Translational Therapeutics in the Cancer Research Institute at BIDMC and Professor of Medicine at Harvard Medical School who co-discovered the enzyme in 1996. "Pin1 is a common key regulator in many types of cancer, and as a result, can control over 50 oncogenes and tumor suppressors, many of which are known to also control cancer stem cells."

Until now, agents that inhibit Pin1 have been developed mainly through rational drug design. Although these inhibitors have proven to be active against Pin1 in the test tube, when they are tested in vitro in a cell model or in vivo in a living animal they are unable to efficiently enter cells to successfully inhibit Pin1 function.

In this new work, co-senior author Xiao Zhen Zhou, MD, an investigator in BIDMC's Division of Translational Therapeutics and Assistant Professor at Harvard Medical School, decided to take a different approach to identify Pin1 inhibitors: She developed a mechanism-based high throughput screen to identify compounds that were targeting active Pin1.

"We had previously identified Pin1 substrate-mimicking peptide inhibitors," explains Zhou. "We therefore used these as a probe in a competition binding assay and screened approximately 8,200 chemical compounds, including both approved drugs and other known bioactive compounds." To increase screening success, Zhou chose a probe that specifically binds to the Pin1 enzyme active site very tightly, an approach that is not commonly used for this kind of screen.

"Initially, it appeared that the screening results had no positive hits, so we had to manually sift through them looking for the one that would bind to Pin1. We eventually spotted cis retinoic acid, which has the same chemical formula as all-trans retinoic acid [ATRA], but with a different chemical structure." It turned out, Zhou explains, that Pin1 prefers binding to ATRA and cis retinoic acid needs to convert ATRA in order to bind Pin1.

ATRA was first discovered for the treatment of acute promyelocytic leukemia (APL) in 1987. "Before tamoxifen or other targeted drugs, there was ATRA," says Lu. It was originally thought that ATRA was successfully treating APL by inducing cell differentiation, causing cancer cells to change into normal cells by activating the cellular retinoic acid receptors. But as these new findings reveal, although this differentiation activity is obvious, it is not the mechanism that is actually behind ATRA's successful outcomes in treating APL.

"While it has been previously shown that ATRA's ability to degrade the leukemia-causing fusion oncogene PML-RAR causes ATRA to stop the leukemia stem cells that drive APL, the underlying mechanism has remained elusive," says Lu. "Our new high throughput drug screening has revealed the ATRA drug target, unexpectedly showing that ATRA directly binds, inhibits and ultimately degrades active Pin1 selectively in cancer cells. The Pin1-ATRA complex structure suggests that ATRA is trapped in the Pin1 active site by mimicking an unreleasable enzyme substrate. Importantly, ATRA-induced Pin1 ablation degrades the fusion oncogene PML-RAR and treats APL in cell and animal models as well as in human patients.

"APL develops when two tumor suppressors fuse together to become an oncogene," adds co-author Pier Paolo Pandolfi, MD, PhD, Director of the Cancer Center at BIDMC whose own pioneering work revealed the molecular underpinnings of APL and led to its cure. "These new findings demonstrate that by inhibiting Pin1, you can degrade this fusion oncogene, thereby stopping cancer stem cells from replicating. This is a critically important discovery that will impact the treatment of other forms of cancer, since Pin1 inhibition is also affecting other key oncogenes."

To that end, the authors also tested ATRA in triple-negative breast cancer, one of the most aggressive types of breast cancer. They discovered that ATRA-induced Pin1 ablation also potently inhibits triple-negative breast cancer growth in human cells and in animal models by simultaneously turning off many oncogenes and turning on many tumor suppressors.

These new results, say the authors, provide a rationale for developing longer half-life ATRA or more potent and specific Pin1-targeted ATRA variants for cancer treatment.

"The current ATRA drug has a very short half life of only 45 minutes in humans," explains Lu. "We think that a more potent Pin1 inhibitor will be able to target many 'dream targets,' that are not currently druggable. ATRA appears to be well tolerated with minimal side effects and offers a promising new approach for targeting a Pin1-dependent common oncogenic mechanism in numerous cancer-driving pathways in cancer and cancer stem cells. This is especially critical for treating aggressive or drug-resistant cancers."

INFORMATION:

In addition to Lu, Zhou, and Pandolfi, co-authors include BIDMC investigators Shuo Wei (first author), Shingo Kozono, Lev Kats, Morris Nechama, Jlenia Guarnerio, Manli Luo, Mi-Hyeon You, Yandan Yao, Asami Kondo, Hai Hu, Markus Reschke, Chun-Hau Chen, and Tae Ho Lee; and colleagues from Harvard Medical School, University of Texas, Austin, University of Sao Paulo, Brazil, Tor Vergata University and Santa Luci Foundation, Rome Italy.

This work was funded, in part, by grants from the National Institutes of Health (R01CA167677, R03DA031663, R01HL111430) and fellowship support from the Susan G. Komen for the Cure Foundation. Lu and Zhou have interests in Pinteon Therapeutics, Inc., which has licensed Pin1 technology from BIDMC.

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.

BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Senior Life and is a research partner of Dana-Farber/Harvard Cancer Center and The Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit http://www.bidmc.org.


ELSE PRESS RELEASES FROM THIS DATE:

Warming seas pose habitat risk for fishy favorites

2015-04-13
Popular North Sea fish such as haddock, plaice and lemon sole could become less common on our menus because they will be constrained to preferred habitat as seas warm, according to a study published today in Nature Climate Change. Fish distributions are limited by water temperature and some species can only thrive in certain habitats and depths. In the last 40 years the North Sea has warmed four times faster than the global average and further warming is predicted over the coming century, leading fisheries scientists to study how this will impact on commercial species. The ...

Some atrial fibrillation patients receive unnecessary blood thinners

2015-04-13
About a quarter of all atrial fibrillation (AF) patients at the lowest risk for stroke receive unnecessary blood thinners from cardiology specialists, according to UCSF researchers, and these providers must be made aware of the resulting potential health risks. Their research letter appears online and will be in the June 1 issue of JAMA Internal Medicine. "The irony is that there is a general push to get providers to prescribe these drugs, and they are also generally under-prescribed among many AF patients who actually need them," said senior author Gregory Marcus, ...

Solution-grown nanowires make the best lasers

Solution-grown nanowires make the best lasers
2015-04-13
MADISON, Wis. - Take a material that is a focus of interest in the quest for advanced solar cells. Discover a "freshman chemistry level" technique for growing that material into high-efficiency, ultra-small lasers. The result, disclosed today [Monday, April 13] in Nature Materials, is a shortcut to lasers that are extremely efficient and able to create many colors of light. That makes these tiny lasers suitable for miniature optoelectronics, computers and sensors. "We are working with a class of fascinating materials called organic-inorganic hybrid perovskites that ...

Babies exposed to narcotic pain relievers more likely to experience withdrawal

2015-04-13
Neonatal abstinence syndrome (NAS), a drug withdrawal syndrome in infants following birth, has historically been associated with illicit drug use among pregnant women. But a study by a team at Vanderbilt University Medical Center shows that pregnant women are commonly being prescribed opioids -- narcotic pain relievers such as hydrocodone -- which results in an increased likelihood of NAS. In addition, the study found that opioid type and duration of exposure combined with tobacco use or selective serotonin reuptake inhibitor use (for treating depression and anxiety) ...

X-ray ptychography, fluorescence microscopy combo sheds new light on trace elements

2015-04-13
ARGONNE, Ill. - Scientists have developed a new approach that combines ptychographic X-ray imaging and fluorescence microscopy to study the important role trace elements play in biological functions on hydrated cells. A team of researchers using the Advanced Photon Source, a U.S. Department of Energy Office of Science User Facility at Argonne National Laboratory, demonstrated unparalleled sensitivity for measuring the distribution of trace elements in thicker specimens at cryogenic temperatures, in this case at about 260 degrees below Fahrenheit. Trace metals are important ...

Mayo profile identifies patients most at risk of developing pancreatic cancer

2015-04-13
JACKSONVILLE, Fla. -- When people find out -- usually from a diagnostic scan looking at something else -- that they have a lesion in their pancreas that could morph into pancreatic cancer, they can panic. They insist on having frequent CT scans and biopsies to monitor the lesion, or they ask for surgery. Physicians also don't know if these abnormalities are dangerous, so the patients end up in surgery having part of their pancreas removed. Often the lesion is nothing to worry about. But a team of international physicians, led by researchers at Mayo Clinic's campus in ...

CNIO experts identify an oncogene regulated by nutrients

CNIO experts identify an oncogene regulated by nutrients
2015-04-13
Scientists from the Growth Factors, Nutrients and Cancer Group at the Spanish National Cancer Research Center (CNIO), led by Nabil Djouder, have discovered that the MCRS1 protein, in response to an excess of nutrients, induces an increase in the activity of mTOR (the mammalian/mechanistic Target of Rapamycin); a protein that is altered in human diseases such as cancer and diabetes, processes associated with ageing, as well as in certain cardiovascular and neurodegenerative pathologies. The finding, published in the journal Developmental Cell, opens up new possibilities ...

New study reveals link between arrival of grandchildren and early retirement of women

2015-04-13
(Washington, D.C.) - According to financial planners, women face unique challenges when preparing to retire. A recent study co-authored by Robin Lumsdaine, Crown Prince of Bahrain Professor of International Finance at American University's Kogod School of Business, reveals retirement-age women who have new grandchildren are 9 percent more likely to retire early than those who do not. The increased probability of early retirement due to the arrival of grandchildren is comparable to the number of women that retire due to worsening health. The decision to retire early has ...

Study: Gene therapy superior to half-matched transplant for 'bubble boy disease'

2015-04-13
(WASHINGTON - April 13, 2015) - New research published online today in Blood, the Journal of the American Society of Hematology (ASH), reports that children with "bubble boy disease" who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder - also known as X-linked severe combined immunodeficiency (SCID-X1) - receiving the two therapeutic approaches. Children with SCID-X1 are born with a genetic defect that ...

Clean up your life with chemistry life hacks (video)

Clean up your life with chemistry life hacks (video)
2015-04-13
WASHINGTON, April 13, 2015 -- Ever run out of your go-to cleaning product, and you've got a mess that you just can't leave alone? Have no fear, chemistry is here. Reactions is back with another round of our Chemistry Life Hacks series, and this week it's all about cleaning. Learn how to make your own glass cleaner, keep red wine from staining your carpet and why spit, yes spit, can also be a great cleaning product. Check out the video here: https://youtu.be/IpG3VClxO3c. INFORMATION:Subscribe to the series at http://bit.ly/ACSReactions, and follow us on Twitter @ACSreactions ...

LAST 30 PRESS RELEASES:

How your brain decides blame and punishment -- and how it can be changed

Uniquely human brain region enables punishment decisions

Pinpointing punishment

Chapman University publishes research on attractiveness and mating

E-cigarettes: Special issue from Nicotine & Tobacco Research

Placental problems in early pregnancy associated with 5-fold increased risk of OB & fetal disorders

UT study: Invasive brood parasites a threat to native bird species

Criminals acquire guns through social connections

Restoring ocean health

Report: Cancer remains leading cause of death in US Hispanics

Twin study suggests genetic factors contribute to insomnia in adults

To be fragrant or not: Why do some male hairstreak butterflies lack scent organs?

International team discovers natural defense against HIV

Bolivian biodiversity observatory takes its first steps

Choice of college major influences lifetime earnings more than simply getting a degree

Dominant strain of drug-resistant MRSA decreases in hospitals, but persists in community

Synthetic biology needs robust safety mechanisms before real world application

US defense agencies increase investment in federal synthetic biology research

Robots help to map England's only deep-water Marine Conservation Zone

Mayo researchers identify protein -- may predict who will respond to PD-1 immunotherapy for melanoma

How much water do US fracking operations really use?

New approach to mammograms could improve reliability

The influence of citizen science grows despite some resistance

Unlocking secrets of how fossils form

What happens on the molecular level when smog gets into the lungs?

Using ultrasound to clean medical instruments

Platinum and iron oxide working together get the job done

Tiny silica particles could be used to repair damaged teeth, research shows

A quantum lab for everyone

No way? Charity's logo may influence perception of food in package

[Press-News.org] Researchers identify drug target for ATRA, the first precision cancer therapy
Discovery offers a new way to fight cancer by targeting the Pin1 enzyme
Press-News.org is a service of DragonFly Company. All Rights Reserved.
Issuers of news releases are solely responsible for the accuracy of their content.